| |
| Advertisement |
 |
| |
|
| |
| Advertisement |
|
nature.com webcasts
Nature Research Custom Media presents a webcast on: Ultra-Sensitive Immunoassays: Beyond Biomarkers and into PK and Immunogenicity
Date: Thursday, June 21, 2018
Dr. Daniel Sikkema, Vice President of Quanterix will present the latest advances in biomarker testing and how to solve drug tolerance and characterization issues for immunogenicity.
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Register for FREE
Sponsored by:
Quanterix | | | |
|
| |
Comment | |
 |
 |
|
| Accelerated approval of medicines: fit for purpose? pp379 - 380
Alasdair Breckenridge & Lawrence Liberti
doi:10.1038/nrd.2017.245
The uptake of a new medicine represents a balance between benefit-risk assessment and value considerations. In the case of products approved via accelerated pathways, the increased uncertainty adds to the challenge. Here, we suggest solutions so that regulators, companies, payers and patients can align around management of the uncertainties and expectations. |
|
News and Analysis | |
|
|
|
| Sepsis researchers set sights on immunotherapeutic strategies pp381 - 383
Asher Mullard
doi:10.1038/nrd.2018.87
Two immune-boosting strategies have independently indicated promise in sepsis clinical trials, after years of failures with anti-inflammatories in this same space. Will it be enough to take sepsis drug development out of 'critical condition'? |
|
|
|
| When drugs unintentionally affect gut bugs pp383 - 384
Cassandra Willyard
doi:10.1038/nrd.2018.88
Many drugs unexpectedly influence the human gut microbiome, showed a recent study, prompting questions about toxicity assays, clinical implications and repurposing opportunities. |
|
|
| News in Brief |
|
|
|
| BACE failures lower AD expectations, again p385
Asher Mullard
doi:10.1038/nrd.2018.94 |
|
|
|
| On the origin of transformative drugs p385
Asher Mullard
doi:10.1038/nrd.2018.95 |
|
|
|
| FDA approves first-in-class SYK inhibitor p385
Asher Mullard
doi:10.1038/nrd.2018.96 |
|
|
| An Audience With |
|
|
|
| Norbert Bischofberger pp386 - 387
doi:10.1038/nrd.2018.82
Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs. |
|
|
| From the analyst's couch |
|
|
|
| What drives site performance in clinical trials? pp389 - 390
Brendan Smith, Linda Martin, Scott Martin, Maria Denslow, Melissa Hutchens, Conrad Hawkins, Valery Panier & Michael S. Ringel
doi:10.1038/nrd.2018.51
This article highlights results from a comprehensive study of the performance of clinical trial sites, which could help companies understand the underlying drivers of success. |
|
| Advertisement |
|
nature.com webcasts
Nature Research Custom presents a webcast on: Multicolour Digital PCR for ctDNA detection in breast cancer
Date: 12 June 2018
Dr. Isaac Garcia-Murillas from ICR will address the technical challenges for clinical utility of liquid biopsy and ctDNA as a biomarker in breast cancer.
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Register for FREE
Sponsored by: Stilla Technologies | | |
|
| |
Research Highlights | |
|
| |
| Advertisement |
|
nature.com webcasts
Nature Research Custom presents a webcast on: Structural Tools In Your MS Tool Box
Date: Wednesday, June 27, 2018
Dr. David Schriemer will provide some insights on how data from electron microscopy, H/D exchange and crosslinking mass spectrometry can be used together to solve complex structure-function problems.
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Register for FREE
Sponsored by: Thermo Fisher Scientific | | |
|
| |
|
 |
Reviews | |
|
|
|
| Interleukin-6: designing specific therapeutics for a complex cytokine pp395 - 412
Christoph Garbers, Sylvia Heink, Thomas Korn & Stefan Rose-John
doi:10.1038/nrd.2018.45
Dysregulation of IL-6 signalling is associated with inflammatory and lymphoproliferative disorders, and several classes of therapeutics have been developed that target components of the IL-6 signalling pathway. This Review describes the progress made in recent years in inhibiting IL-6-signalling and analyses the advantages and disadvantages of these approaches. |
|
|
|
| Post-exposure treatments for Ebola and Marburg virus infections pp413 - 434
Robert W. Cross, Chad E. Mire, Heinz Feldmann & Thomas W. Geisbert
doi:10.1038/nrd.2017.251
Efforts towards developing post-exposure therapies for infections with filoviruses, particularly Ebola and Marburg viruses, increased substantially during the Ebola virus outbreak of 2013-2016. Geisbert and colleagues review the progress made on this front and discuss the challenges and opportunities for developing post-exposure therapies in the future. |
|
|
|
| RNA-modifying proteins as anticancer drug targets pp435 - 453
P. Ann Boriack-Sjodin, Scott Ribich & Robert A. Copeland
doi:10.1038/nrd.2018.71
Covalent modifications of RNA — mediated by RNA-modifying proteins (RMPs) — affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets. |
|
| Advertisement |
|
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.
Click here to sign up. |  | | |
|
| |
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment